IL17A and epilepsy: The main components of KXD for epilepsy may be quercetin, baicalin, kaempferol, yohimbine, geissoschizine methyl ether, baicalein, etc. In conclusion, KXD may exert its therapeutic effect on epilepsy through the following targets: PTGS2, MMP9, CXCL8, ERBB2, and ARG1, acting on the following pathways: neuroactive ligand-receptor interactions, arachidonic acid metabolism, IL-17, TNF, NF-kappaB, and MAPK signaling pathways.